Skip to main content

Table 3 Mean metabolite concentrations by tumour group

From: Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers

 

Ast II

Grade III

GBM

Metastases

Meningioma

Lymphoma

Ace

Ace

0.17 ± 0.10

0.22 ± 0.06

0.19 ± 0.04

0.15 ± 0.02

0.18 ± 0.03

0.40 ± 0.03

Ala

0.30 ± 0.13

1.06 ± 0.31

1.32 ± 0.17

0.81 ± 0.17

2.75 ± 0.46

2.59 ± 1.06

Asc

0.46 ± 0.08

0.58 ± 0.09

0.63 ± 0.10

0.60 ± 0.28

0.82 ± 0.14

2.94 ± 1.41

Asp

0.41 ± 0.13

0.37 ± 0.43

1.14 ± 0.33

0.18 ± 0.12

0.19 ± 0.06

0.73 ± 0.37

Bet

0.14 ± 0.03

0.17 ± 0.06

0.25 ± 0.04

0.10 ± 0.02

0.16 ± 0.03

0.21 ± 0.08

Cho

0.24 ± 0.05

0.26 ± 0.07

0.33 ± 0.05

0.23 ± 0.04

0.23 ± 0.04

0.34 ± 0.03

Cr

3.31 ± 0.80

3.07 ± 1.35

2.99 ± 0.39

1.24 ± 0.21

0.65 ± 0.13

2.07 ± 1.39

Glc

0.53 ± 0.22

0.19 ± 0.13

0.38 ± 0.12

0.64 ± 0.31

0.12 ± 0.07

0.55 ± 0.55

Glu

1.51 ± 0.60

3.01 ± 1.39

2.60 ± 0.33

2.28 ± 0.46

4.94 ± 0.56

4.46 ± 0.42

Gln

5.12 ± 0.56

4.63 ± 1.35

7.11 ± 0.89

2.13 ± 0.32

7.54 ± 0.92

5.44 ± 1.18

GSH

0.52 ± 0.15

0.55 ± 0.11

0.93 ± 0.11

0.96 ± 0.30

2.04 ± 0.25

1.18 ± 0.07

GPC

1.21 ± 0.14

0.77 ± 0.21

0.76 ± 0.14

0.73 ± 0.32

0.26 ± 0.07

0.42 ± 0.15

GPE

0.62 ± 0.13

1.20 ± 0.58

0.41 ± 0.10

0.69 ± 0.15

1.03 ± 0.27

0.60 ± 0.09

Gly

1.59 ± 0.54

1.52 ± 0.47

2.34 ± 0.39

0.75 ± 0.11

1.51 ± 0.22

2.18 ± 0.49

His

0.58 ± 0.13

0.65 ± 0.47

1.67 ± 0.53

0.08 ± 0.06

0.09 ± 0.04

0.82 ± 0.82

h-Tau

0.35 ± 0.12

0.58 ± 0.21

1.16 ± 0.23

0.06 ± 0.03

0.69 ± 0.20

0.36 ± 0.04

Ile

0.13 ± 0.02

0.15 ± 0.04

0.11 ± 0.02

0.25 ± 0.06

0.26 ± 0.06

0.46 ± 0.24

Lac

5.68 ± 0.66

8.91 ± 1.56

9.04 ± 1.07

5.40 ± 0.71

9.81 ± 0.89

8.83 ± 0.76

Leu

0.26 ± 0.03

0.92 ± 0.46

0.51 ± 0.09

0.56 ± 0.10

0.62 ± 0.11

1.14 ± 0.45

Lys

0.52 ± 0.20

0.61 ± 0.12

1.07 ± 0.12

1.05 ± 0.22

1.29 ± 0.17

2.31 ± 0.85

m-Ins

5.23 ± 0.92

2.02 ± 0.83

2.03 ± 0.32

0.70 ± 0.23

0.30 ± 0.08

1.36 ± 0.40

NAA

1.00 ± 0.65

1.14 ± 0.76

0.48 ± 0.15

0.29 ± 0.11

0.07 ± 0.02

1.08 ± 1.07

PCh

0.36 ± 0.12

0.45 ± 0.07

1.56 ± 0.27

0.68 ± 0.11

0.97 ± 0.12

1.10 ± 0.20

PE

0.18 ± 0.05

1.14 ± 0.76

1.97 ± 0.30

1.93 ± 0.30

1.87 ± 0.27

4.55 ± 1.72

s-Ins

0.25 ± 0.05

0.20 ± 0.10

0.20 ± 0.03

0.10 ± 0.03

0.04 ± 0.01

0.26 ± 0.04

Suc

0.11 ± 0.02

0.13 ± 0.04

0.19 ± 0.03

0.14 ± 0.03

0.28 ± 0.04

0.18 ± 0.02

Tau

1.00 ± 0.14

1.00 ± 0.23

0.85 ± 0.11

1.81 ± 0.77

1.75 ± 0.25

2.25 ± 0.74

Thr

0.31 ± 0.06

0.43 ± 0.16

0.66 ± 0.29

0.29 ± 0.07

0.44 ± 0.13

0.90 ± 0.18

Val

0.20 ± 0.04

0.31 ± 0.11

0.20 ± 0.04

0.37 ± 0.04

0.38 ± 0.05

1.02 ± 0.45

  1. The metabolite concentrations of 65 quantified tumour samples grouped into general tumour types (Astrocytoma II, glioma grade III, GBM, metastasis and meningioma). Metabolite concentrations are given (in mM) as group arithmetic means ± the standard error of this mean. Relatively high metabolite concentrations that are referred to in the text as specific markers for particular tumour types are highlighted in bold type. Metabolites, for each tumour type, with a median Cramér-Rao lower-bound of the peak fitting that is greater than 25% of the peak volume, are given in italics.